Neuropsychiatric disorders have been the constant burden impacting healthcare since 1990, and more than 3 billion people worldwide are living with neurological conditions. Mental health conditions with cognitive decline were also observed in people who contracted SARSCoV-2 and later presented the PACS related disease after the resolution of primary infection. 

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive impairments that might be accompanied by declines in activities of daily living, neuropsychiatric disorders and a loss of motor function [1,2]. At present, the prevalence of dementia of Alzheimer’s type (DAT) is approximately 4% among elderly people [3]. With the increase in the aging the population, the number of individuals with DAT is still increasing.

Transfusion Medicine (TM) is a relatively young medical discipline supporting a large number of medical specialties on an almost daily basis. In de routine of TM large amounts of data are collected and processed in a standardized way and depending on the economy of scale practiced. Blood and its components are not without risk when transfused. 

The increasing prevalence of drug-resistant pathogens has highlighted the need for innovative approaches in drug discovery, including drug re-purposing. Artificial intelligence (AI) has emerged as a transformative tool in this endeavor, with the potential to revolutionize not only drug re-purposing for infectious diseases but also the field of hematology.

Epigenetics is the study of heritable modifications to gene expression, such as DNA methylation, histone modifications, and RNA modifications, that do not alter the nucleotide sequence of the corresponding gene. Recently, RNA modification has emerged as a novel research focus.